Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
|
|
- Aubrie Garrett
- 5 years ago
- Views:
Transcription
1 Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown, MD, Taylor S. Riall, MD, PhD
2 OUTLINE Background Review current guidelines for post-treatment surveillance Previous population-based studies Colorectal cancer post-treatment surveillance in Texas
3 COLORECTAL CANCER Siegel, R et al. Cancer Statistics, CA Cancer J Clin Jan;63(1):11-30.
4 COLORECTAL CANCER Siegel, R et al. Cancer Statistics, CA Cancer J Clin Jan;63(1):11-30.
5 PROGNOSIS When detected early, cure is possible with complete resection Up to 30-40% of patients will develop local recurrences or distant metastases after curative resection In most cases, recurrences occur in the first 2-3 years post treatment Viehl, C. T., et al. (2010). Inadequate Quality of Surveillance after Curative Surgery for Colon Cancer. Ann Surg Oncol, 17(10),
6 POST-TREATMENT SURVEILLANCE Goals of post-resection surveillance Identify recurrent cancer or metastatic disease Identify new primary neoplasms Benefits of post-resection surveillance Median five-year overall survival after resection of colorectal liver metastases is 30% (range 12%-41%) Fernandez, FG, et al. Five-year Survival After Resection of Hepatic Metastases from Colorectal Cancer in Patients Screened by Positron Emission Tomography with F-18 Fluorodeoxyglucose (FDG- PET). Ann Surg. 2004; 240:438-47
7 CURRENT GUIDELINES The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend: H&P Every 3-6 months for first 3 years then every 6-12 months for next 2 years CEA testing Every 2-6 months for 2-3 years Colonoscopy One in 1-3 years CT scan chest, abdomen, and pelvis (starting in 2005) Yearly for 3-5 years
8 CONTROVERSIES CT chest, abdomen, and pelvis Recommended for patients at high risk for recurrence Poorly differentiated tumors Lymphovascular invasion CEA New recommendation in 2006 Recommended for patients with Stage II-III disease
9 NON-RECOMMENDED TESTS Liver US Chest x-ray FOBT Fecal DNA testing Barium enemas LFTs MRI PET/PET CT
10 Stage I-III patients 3 academic/university-affiliated institutions Surveillance was left to discretion of treating physician All treating physicians received a letter with surveillance recommendations Median follow-up 33.5 months Viehl, C. T., et al. (2010). Inadequate Quality of Surveillance after Curative Surgery for Colon Cancer. Ann Surg Oncol, 17(10),
11 POPULATION-BASED STUDIES Viehl, C. T., et al. (2010). Inadequate Quality of Surveillance after Curative Surgery for Colon Cancer. Ann Surg Oncol, 17(10),
12 POPULATION-BASED STUDIES Results Overall adherence: 11.6% CEA testing adherence 32.8% 43.6% in those who received chemo vs. 26.8% in those who did not receive chemo (p=0.06) Colonoscopy adherence 23.8% 40.0% in those who received chemo vs. 18.8% in those who did not receive chemo (p=ns) US/CT adherence 31.7% 52.6% in those who received chemo vs in those who did not receive chemo (p=0.07) Viehl, C. T., et al. (2010). Inadequate Quality of Surveillance after Curative Surgery for Colon Cancer. Ann Surg Oncol, 17(10),
13 SEER-Medicare data Stage I-III cancers All patients followed for 3 years starting 6 months after diagnosis Excluded patients not undergoing surgical resection Cooper GS, Kou TD, Reynolds HL. Receipt of guideline-recommended follow-up in older colorectal cancer survivors : a population-based analysis. Cancer 2008; 113(8):
14 POPULATION-BASED STUDIES Guideline met: > 2 office visits/year > 2 CEA tests/year in years 1 and > 1 colonoscopy within 3 years Excess of guidelines: Patient met guidelines and received > 1 CT scan for cancers not poorly differentiated, and/or > 1 PET scan Cooper GS, Kou TD, Reynolds HL. Receipt of guideline-recommended follow-up in older colorectal cancer survivors : a population-based analysis. Cancer 2008; 113(8):
15 POPULATION-BASED STUDIES Results Overall: 17.1% met composite guidelines 22.7% exceeded recommended guidelines 92.3% met surveillance guidelines for office visits 46.7% met guideline-based recommendations for CEA testing 73.6% met guideline-specified criteria for colonoscopy Cooper GS, Kou TD, Reynolds HL. Receipt of guideline-recommended follow-up in older colorectal cancer survivors : a population-based analysis. Cancer 2008; 113(8):
16 POPULATION-BASED STUDIES Factors associated with lack of guideline adherence Local stage Well differentiated tumors Advanced age African American race Increased co-morbidity Cooper GS, Kou TD, Reynolds HL. Receipt of guideline-recommended follow-up in older colorectal cancer survivors : a population-based analysis. Cancer 2008; 113(8):
17 POPULATION-BASED STUDIES 47.7% of patients underwent CT scans 6.8% of patients had > 1 PET scan Factors associated with exceeding recommendations: Younger age Regional cancers Cooper GS, Kou TD, Reynolds HL. Receipt of guideline-recommended follow-up in older colorectal cancer survivors : a population-based analysis. Cancer 2008; 113(8):
18 TCR-Medicare data OBJECTIVES Evaluate adherence to composite guidelines H&P > 2 per year for 3 years CEA tests > 2 per year for 2 years Colonoscopy > 1 in 3 years Evaluate the trends in use of non-recommended cross-sectional imaging studies Describe the impact of oncologic follow up on: Adherence to guidelines Use of non-recommended tests
19 METHODS Used Texas Cancer Registry-Medicare linked data ( ) Surveillance period began 90 days after surgery All patients followed 3 years Guideline adherence and use of non-recommended tests evaluated in patients who survived to the end of the surveillance period Kaplan Meier curves used to evaluate the time to first (and time from first to second) colonoscopy in the overall cohort
20 COHORT SELECTION First primary colon or rectal cancer diagnosed in excluding CIS and stage IV N=34,431 Surgical resection N=12,381 Age 66 and older N=25,612 Exclude ESRD and non-tx residents N=17,520 Patients who survived 3 yrs post treatment N=8,080 Part A/B without HMO 1 yr before and 3 yrs after diagnosis N=13,721
21 PATIENT CHARACTERISTICS 3-year survivors N=8,080 Age (y), mean ± SD Female gender 4337 (53.7%) Race (N=12,365) White 6985 (86.5%) Black 614 (7.6%) Hispanic 339 (4.2%) Charlson Comorbidity Score (64.3%) (22.1%) (8.2%) (5.4%)
22 TUMOR AND TREATMENT CHARACTERISTICS 3-year survivors N=8,080 Tumor Characteristics Colon cancer 6427 (79.5%) Rectal cancer 1653 (20.5%) Local 4422 (54.7%) Regional 3658 (45.3%) Poorly differentiated 1161 (14.4%) Treatment Adjuvant chemotherapy (yes) 2656 (32.9%) Adjuvant radiation (rectal cancer only) 200 (20.9%)
23 ADHERENCE TO GUIDELINES p = NS P = p = 0.018
24 ADHERENCE TO GUIDELINES 3 year survivors Patients with regular PCP follow-up Patients with regular medical oncology follow-up Composite measure Office visits CEA testing Colonoscopy 25.1% 85.4% 29.5% 75.3% 27.7% 100% 31.8% 79.4% 61.5% 100% 70.5% 86.7% Regular follow up = 2 visit per year for three years
25 CEA TESTING 62.1% of patients had at least one CEA measurement 80.0% received a second test within one year of the first 34.6% had one CEA measurement per year for the 3 years 25.5% of patients with local disease 45.6% of patients with regional disease Median time between first and second measurement was 3.7 months
26 TIME TO COLONOSCOPY
27 LOGISTIC REGRESSION ANALYSIS Factor (REF) * Age (> 85 yrs) Guideline adherence OR (95% CI) yrs 2.80 ( ) yrs 2.55 ( ) yrs 2.47 ( ) yrs 1.84 ( ) Stage (Local) 1.48 ( ) PCP visit 2x/3yrs (No) 1.51 ( ) Medical oncologist visit (No) ( ) * Model also adjusted for sex, race, cancer type, tumor differentiation, Charlson comorbidity score, year of diagnosis, and education
28 USE OF CT AND PET/PET CT CT recommended p < p <
29 LOGISTIC REGRESSION ANALYSIS Factor (REF) * Age (> 85 yrs) CT use OR (95% CI) PET/PET CT use OR (95% CI) yrs 1.85 ( ) 2.54 ( ) yrs 1.71 ( ) 2.46 ( ) yrs 1.59 ( ) 2.27 ( ) yrs 1.28 ( ) 1.72 ( ) Cancer (Rectum) 0.60 ( ) 0.61 ( ) Poorly differentiated (No) 1.17 ( ) 1.25 ( ) Regional stage (Local) 1.69 ( ) 1.69 ( ) Medical oncologist visit (No) 3.75 ( ) 4.30 ( ) PCP visit 2x/3yrs (No) 1.27 ( ) 1.07 ( ) * Model also adjusted for sex, race, cancer type, tumor differentiation, Charlson comorbidity score, year of diagnosis, and education
30 SUMMARY Compliance with current minimum guidelines for posttreatment surveillance of colorectal cancer is low The use of CT, PET, and PET/CT has increased over time Adherence to guidelines and use of non-recommended tests is increased in patients followed regularly by a medical oncologist
31 LIMITATIONS Did not look at indications for procedures Surveillance/overuse may be overestimated Use of CEA Some tumors do not have elevated CEA Use in stage I tumors not recommended Patient factors Refusal Not candidate for re-treatment due to co- morbidities
32 FUTURE RESEARCH IDEAS Identify barriers to guideline adherence The comparative effectiveness of ultrasound, CT, and PET/PET CT Dissemination of post treatment surveillance guidelines to patients and physicians
Surveillance of Pancreatic Cancer Patients Following Surgical Resection
Surveillance of Pancreatic Cancer Patients Following Surgical Resection Jaime Benarroch-Gampel, M.D., M.S. CERCIT Scholar CERCIT Workshops March 16, 2012 INTRODUCTION Pancreatic cancer is the 4 th leading
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationDAYS IN PANCREATIC CANCER
HOSPITAL AND MEDICAL CARE DAYS IN PANCREATIC CANCER Annals of Surgical Oncology, March 27, 2012 Casey B. Duncan, Kristin M. Sheffield, Daniel W. Branch, Yimei Han, Yong-Fang g Kuo, James S. Goodwin, Taylor
More informationDepartment of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, 2. College of Medicine, Iowa City, I
Variation in staging and treatment of rectal cancer by National Cancer Institute (NCI) designation and medical school affiliation: Analysis of Surveillance, Epidemiology 1 Department of Epidemiology, University
More informationCARCINOMA DEL COLON-RETTO: COSA DICONO LE LINEE GUIDA. Dr.ssa Foltran Luisa Oncologia medica Pordenone
CARCINOMA DEL COLON-RETTO: COSA DICONO LE LINEE GUIDA Dr.ssa Foltran Luisa Oncologia medica Pordenone Convegno Regionale AIOM FVG, Palmanova, 14 Maggio 2016 COLORECTAL CANCER FOLLOW-UP Objectives Intensive
More informationTitle: What is the role of pre-operative PET/PET-CT in the management of patients with
Title: What is the role of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis? Pablo E. Serrano, Julian F. Daza, Natalie M. Solis June
More informationShore Medical Center Site-Specific Study: Colorectal Cancer 2013
Shore Medical Center Site-Specific Study: Colorectal Cancer Shore Medical Center Site-Specific Study: Colorectal Cancer The following report is the result of a collaborative effort of four physician members
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationStructured Follow-Up after Colorectal Cancer Resection: Overrated. R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007
Structured Follow-Up after Colorectal Cancer Resection: Overrated R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007 Guidelines for Colonoscopy Production: Surveillance US Multi-Society
More informationCOLON AND RECTAL CANCER
No disclosures COLON AND RECTAL CANCER Mark Sun, MD Clinical Assistant Professor of Surgery University of Minnesota Colon and Rectal Cancer Statistics Overall Incidence 2016 134,490 new cases 8.0% of all
More informationColorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial
Colorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial ANNUAL REPOR T (562) 933-0900 MemorialCare.org/TCI 2810 Long Beach Blvd. Long Beach, CA 90806 #3 Colorectal cancer is
More informationBy: Tania Cortas, MD Arizona Oncology 03/10/2015
By: Tania Cortas, MD Arizona Oncology 03/10/2015 Epidemiology In the United States, CRC incidence rates have declined about 2 to 3 percent per year over the last 15 years Death rates from CRC have declined
More informationCOLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
More informationCOLON CANCER FOLLOW UP GUIDELINES
COLON CANCER FOLLOW UP GUIDELINES CAGPO Dr. Raziya Mia October 1, 2016 1 DISCLOSURES NONE 2 MITIGATING POTENTIAL BIAS Recommendations are consistent with published guidelines American Society of Clinical
More informationScreening and Detection in Cancer Survivors. Jose W. Avitia, MD Oncology/Hematology
Screening and Detection in Cancer Survivors Jose W. Avitia, MD Oncology/Hematology Breast Cancer Summary of 2012 ASCO guideline recommendations for surveillance after breast cancer treatment History/physical
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationTHE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER
THE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER Casey A. Boyd, Jaime Benarroch, Kristin M. Sheffield, Yimei Han, Catherine D. Cooksley, Taylor S. Riall Department of Surgery The University of Texas Medical
More informationCOLORECTAL CANCER CASES
COLORECTAL CANCER CASES Case #1 Case #2 Colorectal Cancer Case 1 A 52 year-old female attends her family physician for her yearly complete physical examination. Her past medical history is significant
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationOFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM
OFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM Name: _, OFCCR # _ OCGN # _ OCR Group # _ HIN# Sex: MALE FEMALE UNKNOWN Date of Birth: DD MMM YYYY BASELINE DIAGNOSIS & TREATMENT 1. Place of Diagnosis: Name
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationCOLORECTAL CANCER STAGING in 2010
COLORECTAL CANCER STAGING in 2010 Robert A. Halvorsen, MD, FACR MCV Hospitals / VCU Medical Center Richmond, Virginia I do not have any relevant financial relationships with any commercial interests COLON
More informationCURRENT PRACTICE OF FOLLOW-UP MANAGEMENT AFTER POTENTIALLY CURATIVE RESECTION OF RECTAL CANCER
CURRENT PRACTICE OF FOLLOW-UP MANAGEMENT AFTER POTENTIALLY CURATIVE RESECTION OF RECTAL CANCER 1. a. If you are retired, or do not perform such surgery, please check the box at the right, answer questions
More informationEstablishing a Survivorship Program Within a Large Academic Medical Center
Establishing a Survivorship Program Within a Large Academic Medical Center Andrew J. Ward FNP-BC Surgical Oncology, The University of Tennessee Medical Center Disclosures I have no disclosures. Program
More informationIMAGING GUIDELINES - COLORECTAL CANCER
IMAGING GUIDELINES - COLORECTAL CANCER DIAGNOSIS The majority of colorectal cancers are diagnosed on colonoscopy, with some being diagnosed on Ba enema, ultrasound or CT. STAGING CT chest, abdomen and
More informationVariation in Positron Emission Tomography Use After Colon Cancer Resection
Health Care Delivery Original Contribution Variation in Positron Emission Tomography Use After Colon Cancer Resection By Christina E. Bailey, MD, MSCI, Chung-Yuan Hu, MPH, PhD, Y. Nancy You, MD, MHSc,
More informationRECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
More informationCaring for a Patient with Colorectal Cancer. Objectives. Poll question. UNC Cancer Network Presented on 10/15/18. For Educational Use Only 1
Caring for a Patient with Colorectal Cancer Tammy Triglianos RN, APRN-BC, AOCNP Nurse Practitioner, GI Oncology 10/15/2018 Objectives Describe common signs and symptoms of colorectal cancer Understand
More informationSurveillance after Treatment of Malignancies. John M. Burke, M.D. March 2013
Surveillance after Treatment of Malignancies John M. Burke, M.D. March 2013 Disclosures Advisory Boards Spectrum Alexion Genomic Health Dendreon Seattle Genetics Learning Objectives Improve ability to
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationBOWEL CANCER. Cancer information.
BOWEL CANCER Cancer information www.cancervic.org.au What is bowel cancer? Bowel cancer is the second most common cancer in both men and women in Australia1 and is more common in people over the age of
More informationFollow up The way ahead. John Griffith
Follow up The way ahead John Griffith Key Emerging Principles Risk stratified pathways of care Personalised care plan and treatment summary with a hand held record Information and education Remote monitoring
More informationNEWTON-WELLESLEY HOSPITAL. Standard 4.6: Assessment and Evaluation of Treatment Planning Rectal Cancer
NEWTON-WELLESLEY HOSPITAL Standard 4.6: Assessment and Evaluation of Planning Rectal Cancer Each year a physician member of the cancer committee conducts a study to ensure that diagnostic evaluation and
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationColon cancer is the third most common malignant neoplasm
n clinical n Post-treatment Surveillance in a Large Cohort of Patients With Colon Cancer Chung-Yuan Hu, PhD; George L. Delclos, MD, PhD; Wenyaw Chan, PhD; and Xianglin L. Du, MD, PhD Managed Care & Healthcare
More informationColorectal cancer is the second most common cancer,
PET Changes and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study Andrew M. Scott 1,2, Dishan H. Gunawardana 1, Ben Kelley 3, John
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationIan Landry, MPH Beth Schmidt, MSPH
Mary Charlton, PhD Bobbi Matt, CTR Mary Anne Lynch, MPH Vivien Chen, PhD Ian Landry, MPH Beth Schmidt, MSPH Response to EGFR inhibitors is poorer among Stage IV colorectal cancer (CRC) patients with KRAS
More informationColorectal Cancer Dashboard
Process Risk Assessment Presence or absence of cancer in first-degree blood relatives documented for patients with colorectal cancer Percent of patients with colorectal cancer for whom presence or absence
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationStaging Colorectal Cancer
Staging Colorectal Cancer CT is recommended as the initial staging scan for colorectal cancer to assess local extent of the disease and to look for metastases to the liver and/or lung Further imaging for
More informationEvaluation of Cancer Outcomes Barwon South West Registry
Evaluation of Cancer Outcomes Barwon South West Registry Data Request Form Applicant details Applicant name: Position: Email: Project start date: Date: Telephone: Project completion date: Project details
More informationCancer Survivorship: What to Monitor and When to Intervene. Hyman B. Muss, MD 31 th Miami Breast Cancer Conference 2014
Cancer Survivorship: What to Monitor and When to Intervene Hyman B. Muss, MD 31 th Miami Breast Cancer Conference 2014 Breast Cancer 2013 Incidence Mortality CA: A Cancer Journal for Clinicians pages 52-62,
More informationCASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION
CASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION PROVIDED AS AN EDUCATIONAL SERVICE BY THE INSTITUTE FOR CONTINUING HEALTHCARE EDUCATION SUPPORTED BY AN EDUCATIONAL GRANT FROM GENENTECH LEARNING
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationNavigators Lead the Way
RN Navigators Their Role in patients with Cancers of the GI tract Navigators Lead the Way Nurse Navigator Defined Nurse Navigator A clinically trained individual responsible for the identification and
More informationCOLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE
COLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE Guideline Authors: Todd S. Crocenzi, M.D.; Mark Whiteford, M.D.; Matthew Solhjem, M.D.; Carlo Bifulco, M.D.; Melissa Li, M.D.; Christopher Cai, M.D.;
More informationImaging Surveillance in Women with a History of Treated Breast Cancer. Wei Tse Yang, M.D.
Imaging Surveillance in Women with a History of Treated Breast Cancer Wei Tse Yang, M.D. Breast Cancer 1. Extent 2. Response 3. Recurrence Surveillance Breast Cancer 1. Extent 2. Response Surveillance
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationManagement of colorectal cancer liver metastases
Management of colorectal cancer liver metastases Aliakbarian M. M.D. Assistant professor of surgery Organ Transplant & Hepatopancreatobiliary Surgeon SUBJECTS The importance of surgical resection in colorectal
More informationImaging techniques in the diagnosis, staging and follow up of GI cancers. Moderators: Banke Agarwal, MD and Paul Schultz, MD
Imaging techniques in the diagnosis, staging and follow up of GI cancers Moderators: Banke Agarwal, MD and Paul Schultz, MD Panelists Axel Grothey, MD Professor of Oncology Division of Medical Oncology
More informationSetting The setting was outpatient (ambulatory patients). The economic study was carried out in France.
Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer Lejeune C, Bismuth M J, Conroy T, Zanni C, Bey P,
More informationLower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance
Original Article Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance Dedrick Kok Hong Chan 1,2, Ker-Kan Tan 1,2 1 Division of Colorectal Surgery, University
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationProvider Contribution to Overuse and Underuse of Colorectal Cancer Screening (mostly colonoscopy)
Provider Contribution to Overuse and Underuse of Colorectal Cancer Screening (mostly colonoscopy) James S. Goodwin, MD George and Cynthia Mitchell Distinguished Chair in Geriatric Medicine Director, Sealy
More informationMessage from Leadership
2016 Annual Report 2016 Annual Report Message from Leadership It has been a busy year at the Scotland Cancer Treatment Center. We have welcomed both Dr. Padma Kamineni and Dr. Sireesha Datla to our staff
More informationFollow-up of Patients with Curatively Resected Colorectal Cancer
Evidence-based Series 2-9 EDUCATION AND INFORMATION 2012 Follow-up of Patients with Curatively Resected Colorectal Cancer Members of the Gastrointestinal Cancer Disease Site Group This Evidence-based Series
More informationOutcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study
Original Article Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study Elmer E. van Eeghen 1, Frank den Boer 2, Sandra D. Bakker 1,
More informationNOVA SCOTIA RECTAL CANCER PROJECT: A POPULATION-BASED ASSESSMENT OF RECTAL CANCER CARE AND OUTCOMES. Devon Paula Richardson
NOVA SCOTIA RECTAL CANCER PROJECT: A POPULATION-BASED ASSESSMENT OF RECTAL CANCER CARE AND OUTCOMES by Devon Paula Richardson Submitted in partial fulfilment of the requirements for the degree of Master
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationScreening & Surveillance Guidelines
Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following
More informationColorectal Cancer Awareness: Wiping Out This Disease. Cedrek L. McFadden, MD, FACS, FASCRS
Colorectal Cancer Awareness: Wiping Out This Disease Cedrek L. McFadden, MD, FACS, FASCRS Colorectal Cancer: Statistics ~135,000 estimated new cases 2016 ~50,000 estimated deaths in 2016 (2 nd leading
More informationFollow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care
Follow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 24 November 2018 Disclosures
More informationUsing claims data to investigate RT use at the end of life. B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center
Using claims data to investigate RT use at the end of life B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center Background 25% of Medicare budget spent on the last year of life.
More informationWhen is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool
When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool Adenomas/Carcinoma Sequence Providing Time for Screening Normal 5-20 yrs 5-15 yrs
More informationColon, or Colorectal, Cancer Information
Colon, or Colorectal, Cancer Information Definition Colon, or colorectal, cancer is cancer that starts in the large intestine (colon) or the rectum (end of the colon). Other types of cancer can affect
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationPET in Rectal Carcinoma
Case Report PET in Rectal Carcinoma Josefina Jofré M 1, Paulina Sierralta C 1, José Canessa G 1,2, Pamela Humeres A 3, Gabriel Castro M 4, Teresa Massardo V 1,4 1 Centro PET de Imágenes Moleculares, Hospital
More informationFinancial Disclosure. Team. Race-based Socioeconomic and Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer
Race-based Socioeconomic and Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer Melanie Goldfarb MD, MSc, FACS, FACE John Wayne Cancer Institute at PSJHC, Santa Monica,
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationPROCARE FINAL FEEDBACK
1 PROCARE FINAL FEEDBACK General report 2006-2014 Version 2.1 08/12/2015 PROCARE indicators 2006-2014... 3 Demographic Data... 3 Diagnosis and staging... 4 Time to first treatment... 6 Neoadjuvant treatment...
More informationPerks and Quirks: Using the NCDB Participant User File (PUF) for Outcomes Research
Perks and Quirks: Using the NCDB Participant User File (PUF) for Outcomes Research Daniel J. Boffa, MD Thoracic Surgery Yale University School of Medicine None Disclosures Why Me? No formal affiliation
More informationStage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007
Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Warren L Robinson, MD, FACP May 9, 27 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Colorectal cancer is the third most common cancer
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationHEPATIC METASTASES. We can state 3 types of metastases depending on their treatment options:
HEPATIC METASTASES 1. Definition Metastasis means the spread of cancer. Cancerous cells can separate from the primary tumor and enter the bloodstream or the lymphatic system (the one that produces, stores,
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationHow to integrate surgery in the treatment of patients with liver-only metastatic disease
How to integrate surgery in the treatment of patients with liver-only metastatic disease Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB)
More informationManchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases
Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Date: April 2015 Date for review: April 2018 1. Principles The recognised specialist HPB MDT for Greater
More informationAdjuvant therapy in older adults: controversies and challenges - Colorectal cancer -
International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie
More informationCharacteristics, treatment patterns, and survival outcomes of primary GI melanoma cases compared to cutaneous melanoma, SEER:
Characteristics, treatment patterns, and survival outcomes of primary GI melanoma cases compared to cutaneous melanoma, SEER:1973-2015 Amanda Kahl, MPH Mary E. Charlton, PhD, Imran Hassan, MD, Paolo Goffredo,
More information7/29/2014. Patterns of Care in Colon Cancer ( ) Literature. Background. Florida Cancer Data Compliance with NCCN Guidelines
Patterns of Care in Colon Cancer (21-212) Florida Cancer Data Compliance with FCDS Annual Meeting July 24-25, 214 Caribe Royale Resort Orlando, Florida Background O NCCN guidelines are referenced extensively
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationCOLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE
COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE PROFESSOR OF SURGERY & DIRECTOR, PROFESSIONAL DEVELOPMENT CENTRE J I N N A H S I N D H M E D I C A L U N I V E R S I T Y faisal.siddiqui@jsmu.edu.pk
More informationANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY
ANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY Note: These surveillance recommendations are provided as recommendations only. Clinicians should take into account
More informationA Bridge to Health Men s Health and Cancer
A Bridge to Health Men s Health and Cancer Bertrand Tuan, M.D. Pacific Hematology-Oncology Associates California Pacific Medical Center San Francisco, CA Causes of Cancer Death in California Asian Men
More informationUpdate in Outpatient Medicine JNC 8, Hypertension and More
Update in Outpatient Medicine JNC 8, Hypertension and More March 6 th 2015 Robert Gluckman, MD, FACP CMO Providence Health Plans Disclosures Stock Holdings Abbott Labs Abbvie Bristol Myers Squibb GE Proctor
More informationThis is the portion of the intestine which lies between the small intestine and the outlet (Anus).
THE COLON This is the portion of the intestine which lies between the small intestine and the outlet (Anus). 3 4 5 This part is responsible for formation of stool. The large intestine (colon- coloured
More informationTHE PROCESSES OF CARE AFTER COLORECTAL CANCER SURGERY IN ONTARIO. Jensen Tan. A thesis submitted in conformity with the requirements
THE PROCESSES OF CARE AFTER COLORECTAL CANCER SURGERY IN ONTARIO By Jensen Tan A thesis submitted in conformity with the requirements for the degree of Master of Science (Clinical Epidemiology) Graduate
More information